HK1067073A1 - Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation - Google Patents

Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Info

Publication number
HK1067073A1
HK1067073A1 HK05100604.3A HK05100604A HK1067073A1 HK 1067073 A1 HK1067073 A1 HK 1067073A1 HK 05100604 A HK05100604 A HK 05100604A HK 1067073 A1 HK1067073 A1 HK 1067073A1
Authority
HK
Hong Kong
Prior art keywords
gram positive
treatment
positive bacteria
diseases
immune dysregulation
Prior art date
Application number
HK05100604.3A
Other languages
English (en)
Inventor
Marie-Anne Nahori
Micheline Lagranderie
Gilles Marchal
Bernardo Boris Vargaftig
Jean Lefort
Felix Romain
Georges Hekimian
Philippe Peltre
Original Assignee
Pasteur Institut
Inst Nat Sante Rech Med
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pasteur Institut, Inst Nat Sante Rech Med filed Critical Pasteur Institut
Publication of HK1067073A1 publication Critical patent/HK1067073A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Pulmonology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Biochemistry (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Transplantation (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
HK05100604.3A 2001-12-11 2005-01-21 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation HK1067073A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP01403195 2001-12-11
PCT/IB2002/005760 WO2003049752A2 (en) 2001-12-11 2002-12-11 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Publications (1)

Publication Number Publication Date
HK1067073A1 true HK1067073A1 (en) 2005-04-01

Family

ID=8183013

Family Applications (1)

Application Number Title Priority Date Filing Date
HK05100604.3A HK1067073A1 (en) 2001-12-11 2005-01-21 Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation

Country Status (18)

Country Link
US (3) US20060062807A1 (zh)
EP (2) EP1461054B1 (zh)
JP (2) JP4737586B2 (zh)
KR (2) KR101048798B1 (zh)
CN (1) CN1602199B (zh)
AT (1) ATE466585T1 (zh)
AU (1) AU2002356387C1 (zh)
BR (1) BR0214902A (zh)
CA (1) CA2469334C (zh)
CY (1) CY1110727T1 (zh)
DE (1) DE60236318D1 (zh)
DK (2) DK1461054T3 (zh)
ES (1) ES2345188T3 (zh)
HK (1) HK1067073A1 (zh)
NZ (2) NZ555055A (zh)
PT (1) PT1461054E (zh)
SI (1) SI1461054T1 (zh)
WO (1) WO2003049752A2 (zh)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR0214902A (pt) * 2001-12-11 2004-11-30 Pasteur Institut Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos
SI1534330T1 (sl) * 2002-09-06 2014-08-29 Ucl Business Plc Cele bakterijske celice kot imunomodulatorji
US7413728B2 (en) 2003-11-14 2008-08-19 Ucl Biomedica Plc Immune modulator
EP1730171A1 (en) 2004-02-19 2006-12-13 Ramot at Tel Aviv University Ltd. Peptide mimotopes of mycobacterial mannosylated lipoglycans and uses thereof
US9107864B2 (en) 2004-06-07 2015-08-18 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
US8501198B2 (en) 2004-06-07 2013-08-06 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to treat cancers
NZ586338A (en) * 2004-06-07 2012-02-24 Qu Biolog Inc Bacterial compositions for the treatment of cancer
US8034359B2 (en) 2004-06-07 2011-10-11 Qu Biologics Inc. Tissue targeted antigenic activation of the immune response to cancers
WO2006001011A1 (en) 2004-06-24 2006-01-05 Yissum Research Development Company Use of mycobacterial mannosylated lipoglycans peptide mimotopes for treating inflammation
CA2531261A1 (en) * 2005-12-21 2007-06-21 Institut Pasteur Control of intestinal inflammatory syndromes with a preparation of killed or non infectious bacteria
NZ715882A (en) * 2006-10-27 2017-07-28 Qu Biologics Inc Tissue targeted antigenic activation of the immune response to treat cancers
GB0716778D0 (en) * 2007-08-29 2007-10-10 Bioeos Ltd Use
EP2087898A1 (en) * 2008-02-06 2009-08-12 Institut Pasteur A preparation of mycobacterium bovis BCG killed by extended freeze drying (EFD) for treating rheumatoid arthritis
CA2629057A1 (en) * 2008-04-14 2009-10-14 Institut Pasteur Control of diseases associated with decrease of t-regulatory cells with a preparation of extended freeze-dried killed bacteria
HUP0900231A2 (hu) * 2009-04-16 2010-11-29 Hyd Rakkutato Es Gyogyszerfejlesztoe Kft Allergiás betegségek kezelésére, gyógyítására alkalmas készítmények és eljárás azok elõállítására
EP2292260A1 (en) 2009-08-13 2011-03-09 Institut Pasteur Use of mycobacterium bovis BCG killed by extended freeze drying (EFD) for preventing or treating atherosclerosis
EP2620159A1 (en) 2012-01-24 2013-07-31 Institut Pasteur Improved cancer treatment by immunotherapy with bcg or antigenically related non-pathogenic mycobacteria
US10251946B2 (en) 2014-05-02 2019-04-09 Qu Biologics Inc. Anti-microbial immunomodulation
WO2017143386A1 (en) * 2016-02-25 2017-08-31 Borody Thomas J Compositions and methods of treatment of chronic infectious diseases
CN113226342A (zh) * 2018-10-17 2021-08-06 西巴克股份有限公司 治疗和预防肺部状况的活的生物治疗剂
US20220047648A1 (en) * 2019-01-09 2022-02-17 Md Healthcare Inc. Nanovesicles derived from bacteria of genus rhodococcus, and use thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2594471A (en) * 1946-10-11 1952-04-29 Comb Eng Superheater Inc Heat exchange apparatus
GB764718A (en) * 1954-08-10 1957-01-02 Glaxo Lab Ltd Improvements in or relating to freeze-drying processes
GB1027979A (en) * 1963-07-12 1966-05-04 Ciba Ltd Process for obtaining bcg-cultures
GB1163470A (en) * 1967-11-13 1969-09-04 Cecil Arthur Clark Improvements in or relating to Adjuvant Vaccines
JPS57186495A (en) 1981-05-14 1982-11-16 Ube Ind Ltd Preparation of l-alpha-methylphenylalanine
GB8404280D0 (en) 1984-02-17 1984-03-21 Stanford J L Biological preparations
NZ216119A (en) 1985-05-13 1989-01-06 Commw Scient Ind Res Org Vaccine produced using antigens of a pseudocapsule producing strain of s.aureus
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
JPS63126830A (ja) * 1986-11-17 1988-05-30 Isao Moriya 動植物の体内に抗体を生成する方法
US4897268A (en) 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
GB9801870D0 (en) * 1998-01-28 1998-03-25 Raby Limited Vaccine composition
SE9900495D0 (sv) * 1999-02-12 1999-02-12 Pharmatrix Ab Vaccine composition
US6350457B1 (en) * 1999-06-02 2002-02-26 Genesis Research & Development Corporation Limited Methods and compounds for the treatment of immunologically-mediated diseases using mycobacterium vaccae
BR0214902A (pt) 2001-12-11 2004-11-30 Pasteur Institut Preparação bacteriana, frações de preparação bacteriana, composição farmacêutica, uso da preparação bacteriana ou suas frações, método para a produção da preparação de bactérias mortas liofilizadas estendidas, kit para o tratamento de uma doença compreendendo uma desregulação imune, e, produtos

Also Published As

Publication number Publication date
US7871627B2 (en) 2011-01-18
CN1602199B (zh) 2012-04-04
JP2011121977A (ja) 2011-06-23
KR101048798B1 (ko) 2011-07-15
CN1602199A (zh) 2005-03-30
WO2003049752A3 (en) 2003-11-20
WO2003049752A2 (en) 2003-06-19
NZ555055A (en) 2010-06-25
US8404250B2 (en) 2013-03-26
EP2316466B1 (en) 2013-08-21
CA2469334C (en) 2012-05-08
CY1110727T1 (el) 2015-06-10
SI1461054T1 (sl) 2010-09-30
DK1461054T3 (da) 2010-08-16
JP2005516915A (ja) 2005-06-09
BR0214902A (pt) 2004-11-30
AU2002356387C1 (en) 2008-03-06
DK2316466T3 (da) 2013-11-18
JP4737586B2 (ja) 2011-08-03
EP2316466A2 (en) 2011-05-04
KR20040080434A (ko) 2004-09-18
NZ533422A (en) 2008-03-28
JP5417354B2 (ja) 2014-02-12
EP1461054B1 (en) 2010-05-05
PT1461054E (pt) 2010-08-09
ES2345188T3 (es) 2010-09-17
US20100272756A1 (en) 2010-10-28
KR101124363B1 (ko) 2012-03-21
ATE466585T1 (de) 2010-05-15
EP1461054A2 (en) 2004-09-29
DE60236318D1 (de) 2010-06-17
AU2002356387B2 (en) 2007-09-13
US20060062807A1 (en) 2006-03-23
CA2469334A1 (en) 2003-06-19
US20070190076A1 (en) 2007-08-16
EP2316466A3 (en) 2012-04-11
KR20110028558A (ko) 2011-03-18
AU2002356387A1 (en) 2003-06-23

Similar Documents

Publication Publication Date Title
HK1067073A1 (en) Gram positive bacteria preparations for the treatment of diseases comprising an immune dysregulation
WO2001090129A3 (en) Prophylactic and therapeutic treatment of infectious, autoimmune and allergic diseases with mono and disaccharide-base compounds
WO2003096990A3 (en) Protein cages for the delivery of medical imaging and therapy
WO2004069156A3 (en) Inactivated probiotic bacteria and methods of use thereof
HK1087398A1 (en) 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases
EP1783126A3 (en) N-oxides of N-phenyl-2-pyrimidine-amine derivatives
WO2002085299A3 (en) Therapeutic treatments using the direct application of antimicrobial metal compositions
WO2003099771A3 (en) Diaryl urea derivatives useful for the treatment of protein kinase dependent diseases
ATE556706T1 (de) Fettalkohol-arzneimittel-konjugate
EP1262177A3 (en) Medical use of thyromimetic compounds to treat hair loss and compositions
HK1067051A1 (en) Use of osteopontin for the preparation of medicinein treatment and/or prevention of neurologic dise ases
AU4073901A (en) Novel pharmaceutical or dietetic mushroom-based compositions
WO2004031129A3 (en) Compounds for use in the treatment of autoimmune diseases, immuno-allergical diseases and organ or tissue transplantation rejection
WO2006004588A3 (en) Immunodynamic complexes and methods for using and preparing such complexes
WO2002078741A3 (en) Methods and compositions for modulating the immune system of animals
MXPA03003741A (es) Metodos y composiciones para el tratamiento de enfermedades oftalmicas.
IL161501A0 (en) Methods of preventing and treating flavivirus infection in animals
WO2005094790A8 (es) Formulaciones liposomales
ATE458004T1 (de) Osteoprotegerin in milch
EP1303300A4 (en) COMPOSITIONS AND METHODS FOR TREATING CANDIDIASIS
WO2003013440A3 (en) Treatment and prevention of heat shock protein-associated diseases and conditions
MXPA04007491A (es) Tratamiento profilactico y terapeutico de infecciones y otras enfermedades con compuestos inmunoefectores.
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2001095937A3 (en) Phytoestrogenic isoflavone compositions
WO2002066492A3 (fr) Anticorps specifique de l'adrenomedulline humaine, composition pharmaceutique le contenant, ses applications therapeutiques.

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20161211